Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (5531)	1/24/2002 12:41:30 PM
From: scott_jiminez	Read Replies (3) of 52153

<<The main caveat here is that we haven't seen any scientific publications, so we are going basically from company PR.>> That's not a caveat. That's a HUGE problem in the specific case you cite and it has been a pernicious and endemic problem in the BT sector for eons. When a investor reads a 'caveat' like that, he/she should stop reading immediately and move on. PERIOD. Investors should ONLY believe data that appears in peer-reviewed journals. Investors should TOTALLY DISCOUNT the nonsense that comes from the lips of BT CEOs as pure PR. It never ceases to surprise me how otherwise intelligent BT-associated folks suspend disbelief when it comes to company-released data. In this time of Enron and IMCL investors should invoke the highest degree of skepticism towards self-proclamations from BT companies regarding their products. Caveat emptor -there is no other sector where this truism applies more than BT. DON'T BUY THE CEO'S DOUBLETALK! IF THE COMPANY DOESN'T PUBLISH IT'S DATA IN A PEER REVIEWED JOURNAL...RUN LIKE HELL FROM THE STOCK!!!!!!! There can be no more basic lesson in BT investing than this. I thought this was obvious.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next